Grifols and Andorran government agree not to proceed with immunology research center

Barcelona, Spain, July 25, 2024 – Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino.

Grifols and Andorra Development and Investment (ADI), the principality’s economic promotion agency, have decided to formerly dissolve the joint venture established to manage the project, the Pyrenees Immunology Research Center.

Grifols will instead advance its scientific work on immunology as well as other key therapeutic areas through its interconnected network of 13 existing global research centers located in hubs in North America and Europe.

“Grifols would like to thank the Andorran government and everyone who has supported the project for their outstanding commitment to innovation and science,” said Daniel Fleta, Grifols Chief Industrial Services Officer. “Grifols will continue to innovate breakthrough medicines and healthcare solutions through our existing R&D network.”

“While the government of Andorra regrets not being able to move forward with the immunology research center – and we thank Grifols for its collaboration during this time – Andorra remains committed to further diversifying our economy with priority sectors such as biotechnology and other life sciences,” said Conxita Marsol, Andorra’s Minister of Presidency, Economy, Work and Housing.

Grifols and the Andorran government first began working together during the pandemic, when Grifols facilitated testing for the SARS-CoV-2 virus. They have left the door open to future collaborations in healthcare.